Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

BREAKING NEWS
Thailand Medical News Team  Aug 26, 2023  6 months, 2 days, 21 hours, 24 minutes ago

Italian Study Finds That Supplementation With Palmitoylethanolamide And Luteolin Improves Long COVID Conditions

861 Shares
facebook sharing button Share
twitter sharing button Tweet
linkedin sharing button Share
Italian Study Finds That Supplementation With Palmitoylethanolamide And Luteolin Improves Long COVID Conditions
Thailand Medical News Team  Aug 26, 2023  6 months, 2 days, 21 hours, 24 minutes ago
Long COVID: In the wake of the unprecedented global COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medical communities have been grappling with the challenges posed by both the acute infection and its lingering aftermath. The phenomenon commonly referred to as "Long COVID" has emerged as a complex and enigmatic condition characterized by a constellation of symptoms that persist well beyond the acute phase of the disease. A groundbreaking Italian study, conducted collaboratively by medical professionals from the Sistema Sanitario Regionale-Italy, Catholic University of Sacred Heart-Italy, and University of Messina-Italy, has shed light on a potential avenue of treatment for Long COVID. The study specifically explored the effects of supplementing with Palmitoylethanolamide co-ultramicronized with Luteolin (PEALUT) in alleviating the array of symptoms experienced by Long COVID patients.


 
Understanding Long COVID
Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), is a perplexing and debilitating condition that affects individuals who have recovered from the acute phase of COVID-19. It is characterized by an array of persistent symptoms, ranging from physical manifestations such as pain, fatigue, and loss of smell and taste to neuropsychiatric symptoms like depression, anxiety, and cognitive impairments often referred to as "brain fog." This condition has a significant impact on individuals' quality of life, hampering their ability to resume normal daily activities.
 
The medical community has been grappling with the challenge of treating Long COVID due to the diverse and often elusive nature of its symptoms. The lack of a standardized approach and the absence of proven treatment protocols have only exacerbated the burden of this condition on patients and healthcare systems worldwide.
 
Palmitoylethanolamide co-ultramicronized with Luteolin:  A Novel Treatment Approach
The Italian study sought to evaluate the potential benefits of Palmitoylethanolamide co-ultramicronized with Luteolin (PEALUT) in addressing the multi-faceted symptomatology of Long COVID. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that plays a crucial role in modulating inflammation and maintaining tissue homeostasis. It exerts its effects through interactions with specific receptors involved in immune response regulation.
 
However, PEA's therapeutic potential has been limited by challenges related to its bioavailability when administered orally.
 
To address this, researchers have developed ultramicronized formulations of PEA, which enhance its absorption and distribution in the body. The combination of PEA with luteolin, a polyphenol with potent antioxidant and neuroprotective properties, further enhances the therapeutic potential of this compound.
 
Retrospective Analysis on Long COVID Patients
The study involved a retrospective analysis conducted by a group of nine General Practitioners based in the Rome area of Italy. These medical professionals observed and recorded the effects of PEALUT supplementation on their Long COVID patients. The study's design aimed to evaluate the impact of PEALUT on a wide range of symptoms, from pain and fatigue to cognitive impairments and psychological distress.
 
The study team utilized standardized assessment tools to measure changes in symptoms and overall health status before and after PEALUT supplementation. These tools included the Patient Global Impression of Change (PGIC) scale, which gauges patients' perception of their own health improvement, and the Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A) to assess changes in mood-related symptoms.
 
Promising Results and Implications
The outcomes of the study were highly encouraging. Patients who received PEALUT supplementation exhibited significant improvements across a spectrum of symptoms. Notably, pain intensity, fatigue, cognitive impairments, and psychological distress all showed marked amelioration following the treatment. Anosmia and dysgeusia, which are common sensory impairments associated with Long COVID, also saw notable improvements.
 
Equally significant were the positive shifts in patients' self-perceived health status. More than 95% of patients reported feeling improved after the PEALUT treatment. This indicates that the treatment not only targeted specific symptoms but also contributed to a broader enhancement of patients' overall well-being.
 
The Role of General Practitioners
One particularly noteworthy implication of this study is the central role that General Practitioners (GPs) can play in the management of Long COVID. GPs are often the first point of contact for patients experiencing lingering symptoms after recovering from COVID-19. Their familiarity with patients and their comprehensive understanding of medical histories positions them to identify and address Long COVID cases in their early stages.
 
The study's findings underscore the importance of a patient-centered approach that emphasizes the empathetic and supportive role that GPs can play. By employing easily accessible tools such as PEALUT supplementation, GPs have the potential to substantially contribute to the mitigation of Long COVID's impact.
 
Future Directions and Conclusions
While the results of this retrospective analysis are promising, it's essential to acknowledge the preliminary nature of the findings. The absence of a control group and the potential for natural symptom resolution over time necessitate further investigation to establish the true efficacy of PEALUT. Randomized, prospective, controlled clinical trials are the logical next step to validate these initial results.
 
In conclusion, the Italian study offers a glimmer of hope in the realm of Long COVID treatment. The collaboration between medical professionals from various disciplines, coupled with the innovative approach of supplementing with PEALUT, represents a significant step forward in addressing the persistent and wide-ranging symptoms of this condition. As the world continues to grapple with the multifaceted challenges posed by Long COVID, studies like this provide both insights and potential solutions to alleviate the burden on patients and healthcare systems alike.
 
The study findings were published in the peer reviewed journal: Nutrients.
https://www.mdpi.com/2072-6643/15/17/3701
 
For the latest on Long COVID, keep on logging to Thailand Medical News.

MOST READ

Jun 10, 2023  9 months ago
COVID-19 News - DNA Methylation - Asymptomatic SARS-CoV-2 Infections
Sep 08, 2022  1 year ago
Source- Medical News - COVID-19 Research - Impaired Pain Modulation
Aug 04, 2022  2 years ago
Source: Medical News - SARS-CoV-2 & Cancer
Aug 13, 2020  4 years ago
Source: Supplements For COVID-19